Usefulness of hypoxia inducible factor-1 alpha in evaluating the prostatic adenocarcinoma viability following neoadjuvant hormone therapy

Cancer Detection and Prevention

Volumn 31, Issue 5, 2007, Pages 396-401

  Yasuda, Masanori ^a   Shimizu, Michio ^a   Fujita, Mariko ^b   Miyazawa, Masaki ^b   Tang, Xiaoyan ^b   Kajiwara, Hiroshi ^b   Osamura, Robert Yoshiyuki ^b   Shoji, Sunao ^b   Tokunaga, Masatoshi ^b   Terachi, Toshiro ^b  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b TOKAI UNIVERSITY   (Japan)

Author keywords

Hormone therapy; Hypoxia inducible factor 1 alpha (HIF 1 ); Prostatic cancer

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN DERIVATIVE; GOSERELIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER HORMONE THERAPY; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; HORMONE ANTAGONISTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IMMUNOHISTOCHEMISTRY; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 36448933775     PISSN: 0361090X     EISSN: 15251500     Source Type: Journal    
DOI: 10.1016/j.cdp.2007.10.007     Document Type: Article

References (23)

1. Kimbro K.S., and Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13 (2006) 739-749
2. Semenza G.L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trend Mol Med 8 (2002) 62-67
3. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci U.S.A. 95 (1998) 7987-7992
4. 2 tension. Am J Physiol 271 (1996) 1172-1180
5. Maxwell P.H., Wiesener M.S., Chang G.W., Clifford S.C., Vaux E.C., Cockman M.E., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
6. Zhong H., Semenza G.L., Simons J.W., and De Marzo A.M. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect Prev 28 (2004) 88-93
7. Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22 (2002) 7004-7014
8. Madjeesh N.J., Post D.E., Willard M.T., Kaur B., Van Meir E.G., Simons J.W., et al. Geldanamycin induces degradation of hypoxia-inducible factor 1alpha protein via the proteosome pathway in prostate cancer cells. Cancer Res 62 (2002) 2478-2482
9. Mabjeesh N.J., Willard M.T., Frederickson C.E., Zhong H., and Simons J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9 (2003) 2416-2425
10. Palayoor S.T., Tofilon P.J., and Coleman C.N. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res 9 (2003) 3150-3157
11. Thomas R., and Kim M.H. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 334 (2005) 543-548
12. Tokunaga M., Yasuda M., Osamura R.Y., Itoh J., Mukai M., Shima M., et al. Association of neuroendocrine differentiation with neoadjuvant hormone therapy effects in prostatic cancer. Oncol Rep 13 (2005) 1081-1087
13. Kyprianou N., English H.F., and Isaacs J.T. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 50 (1990) 3748-3753
14. Cookson M.S., Sogani P.C., Russo P., Sheinfeld J., Herr H., Dalbagni G., et al. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer: results of a phase II study. Br J Urol 79 (1997) 432-438
15. Fair W.R., Cookson M.S., Stroumbakis N., Cohen D., Aprikian A.G., Wang Y., et al. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49 (1997) 46-55
16. Klotz L.H., Goldenberg S.L., Jewett M., Barkin J., Chetner M., Fradet Y., et al., Canadian Urologic Oncology Group. CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Urology 53 (1999) 757-763
17. Soloway M.S., Sharifi R., Wajsman Z., Mcleod D., Wood D.P., Puras-Baez A., and The Lupron Depot Neoadjuvant Prostate Cancer Study Group. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 154 (1995) 424-428
18. Labrie F., Cusan L., Gomez J.L., Diamond P., Suburu R., Lemay M., et al. Down-staging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinzing hormone-releasing hormone agonist. Urology 44 (1994) 29-37
19. Kitagawa Y., Koshida K., Mizokami A., Komatsu K., Nakashima S., Misaki T., et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. Int J Urol 10 (2003) 377-382
20. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
21. Du Z., Fujiyama C., Chen Y., and Masaki Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J 116 (2003) 1936-1939
22. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostatic cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60 (2000) 1541-1545
23. Tan C., de Noronha R.G., Roecker A.J., Pyrzynska B., Khwaja F., Zhang Z., et al. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res 65 (2005) 605-612